Literature DB >> 8698628

Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins.

K Koike1, T Abe, T Hisano, T Kubo, M Wada, K Kohno, M Kuwano.   

Abstract

Overexpression of either the multidrug resistance 1 (MDR1) gene or multidrug resistance protein (MRP) gene is involved in acquisition of multidrug-resistant phenotypes in human cancer cells. In this study we examined whether selection for resistance to the epipodophyllotoxins, etoposide/teniposide (VP16/VM26), could induce overexpression of MDR1 or MRP. We have previously isolated two VP16/VM26-resistant KB cell lines. Two VP16/VM26-resistant KB cell lines, KB/VM-1 and KB/ VM-4, which were selected by stepwise exposure to VM26 had decreased accumulation of [3H]VP16 and increased levels of MRP, but no apparent expression of MDR1 gene was observed. Another VP16/VM26-resistant KB cell line, KB/VP-4, which was further isolated from a VP16-resistant KB cell line, KB/VP-2, had decreased accumulation of [3H]VP16 and showed overexpression of MRP gene, but not that of MDR1 gene. We also isolated a VP16-resistant cell line, IN157/VP-1, from a human glioma cell line IN157. IN157/VP-1 cells showed decreased accumulation of [3H]VP16 and overexpression of MRP gene, but not of MDR1. These findings suggest that selection for resistance to VP16/VM26, preferentially induces overexpression of MRP gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698628      PMCID: PMC5921162          DOI: 10.1111/j.1349-7006.1996.tb00290.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  40 in total

Review 1.  DNA topoisomerase-targeting antitumor agents and drug resistance.

Authors:  H Takano; K Kohno; K Matsuo; T Matsuda; M Kuwano
Journal:  Anticancer Drugs       Date:  1992-08       Impact factor: 2.248

Review 2.  Multidrug resistance.

Authors:  A M van der Bliek; P Borst
Journal:  Adv Cancer Res       Date:  1989       Impact factor: 6.242

3.  Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.

Authors:  H Takano; K Kohno; M Ono; Y Uchida; M Kuwano
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

4.  DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.

Authors:  T Kubo; K Kohno; T Ohga; K Taniguchi; K Kawanami; M Wada; M Kuwano
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

Review 5.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

6.  Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene.

Authors:  G D Kruh; A Chan; K Myers; K Gaughan; T Miki; S A Aaronson
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

7.  Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies.

Authors:  M J Flens; M A Izquierdo; G L Scheffer; J M Fritz; C J Meijer; R J Scheper; G J Zaman
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

8.  Reversal by a dihydropyridine derivative of non-P-glycoprotein-mediated multidrug resistance in etoposide-resistant human prostatic cancer cell line.

Authors:  Y Tasaki; M Nakagawa; J Ogata; A Kiue; H Tanimura; M Kuwano; Y Nomura
Journal:  J Urol       Date:  1995-09       Impact factor: 7.450

9.  Vincristine-resistant human cancer KB cell line and increased expression of multidrug-resistance gene.

Authors:  K Kohno; J Kikuchi; S Sato; H Takano; Y Saburi; K Asoh; M Kuwano
Journal:  Jpn J Cancer Res       Date:  1988-11

10.  Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.

Authors:  S Hasegawa; T Abe; S Naito; S Kotoh; J Kumazawa; D R Hipfner; R G Deeley; S P Cole; M Kuwano
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more
  8 in total

1.  Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and exhibits 3'-->5' exonuclease activity.

Authors:  H Izumi; T Imamura; G Nagatani; T Ise; T Murakami; H Uramoto; T Torigoe; H Ishiguchi; Y Yoshida; M Nomoto; T Okamoto; T Uchiumi; M Kuwano; K Funa; K Kohno
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

Review 2.  Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions.

Authors:  Li Xing; Yiding Hu; Yurong Lai
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

3.  Expression of multidrug resistance protein gene in patients with glioma after chemotherapy.

Authors:  T Abe; T Mori; Y Wakabayashi; M Nakagawa; S P Cole; K Koike; M Kuwano; S Hori
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

Review 4.  Programming of Cell Resistance to Genotoxic and Oxidative Stress.

Authors:  Ilya O Velegzhaninov; Vitaly A Ievlev; Yana I Pylina; Dmitry M Shadrin; Olesya M Vakhrusheva
Journal:  Biomedicines       Date:  2018-01-02

5.  Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.

Authors:  S Hirata; O Katoh; T Oguri; H Watanabe; K Yajin
Journal:  Jpn J Cancer Res       Date:  2000-01

6.  The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.

Authors:  M Tomonaga; M Oka; F Narasaki; M Fukuda; R Nakano; H Takatani; K Ikeda; K Terashi; I Matsuo; H Soda; K H Cowan; S Kohno
Journal:  Jpn J Cancer Res       Date:  1996-12

7.  An In Silico Classification Model for Putative ABCC2 Substrates.

Authors:  Marta Pinto; Michael Trauner; Gerhard F Ecker
Journal:  Mol Inform       Date:  2012-08-09       Impact factor: 3.353

8.  Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer.

Authors:  E Syahruddin; T Oguri; T Takahashi; T Isobe; Y Fujiwara; M Yamakido
Journal:  Jpn J Cancer Res       Date:  1998-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.